MoonLake Immunotherapeutics

MLTX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$11.47-2.63%

2026-11-02

Financials

Valuation Metrics

MoonLake Immunotherapeutics's Market Cap is $844M. At end of 2025 it was $850M. Ranked #2465 of 3,116 in US market (top 79%), #1015 of 1,472 on NASDAQ (top 69%), #186 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 70%) by Market Cap.

Investment Metrics(as of 2026-11-02)

Metric	Value	Rank
Size
Market Cap	$844M	US#2,465/3,116 Sec#186/265
Revenue	$0.00	US#2,859/3,116 Sec#193/265
Net Income	$-264M	US—/3,116 Sec—/265
Total Assets	$574M	US#2,704/3,116 Sec#144/265
Net Assets	$428M	US#2,318/3,116 Sec#124/265
Value
P/B	1.97x	US#1,357/3,116 Sec#68/265
FCF Yield	-26.67%	US—/3,116 Sec—/265
Profitability
ROE	-61.58%	US#2,714/3,116 Sec#176/265
ROA	-45.94%	US#2,968/3,116 Sec#203/265
Financial Health
Debt Ratio	34.04%	US#386/3,116 Sec#114/265
Total Debt	$102M	US#2,425/3,116 Sec#119/265
FCF	$-225M	US#2,801/3,116 Sec#218/265
Cash	$478M	US#1,101/3,116 Sec#60/265
Current Ratio	12.56x	US#192/3,116 Sec#60/265
Performance
1Y Return	13.56%	US#884/3,116 Sec#95/265
1M Return	0.53%	US#752/3,116 Sec#55/265
From 52W High	-50.75%	US#2,561/3,116 Sec#192/265
1Y MDD	-56.90%	US#2,646/3,116 Sec#192/265
Trading
Volume	914,107 shares	US#462/3,116 Sec#40/265
Trading Value	$11M	US#1,287/3,116 Sec#91/265
Per Share
EPS	$-3.58	US—/3,116 Sec—/265
BPS	$5.82	US#2,209/3,116 Sec#117/265